Abstract

Overview of Predictive Biomarkers of Cancer Therapy

Sherry Yang, Chief, National Clinical Target Validation Laboratory, National Cancer Institute

The speech will briefly summarize the established biomarkers in cancer patient care, which introduces our insights into the systemic classification and clinical application of predictive/therapeutic biomarkers for targeted cancer therapy and chemotherapy. These include, i, biomarkers for clinical benefit or response; ii, resistance to treatment; iii, risk identification and iv, those for dose selection guidance or toxicity. The technology platforms currently used for the established biomarkers will be discussed. The steady advances in the development of targeted cancer therapy particularly with the rapid progress of immunotherapy continues to assure the increased success and reduced toxicity in the management of cancer patients.